These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35476706)

  • 1. Extended Versus Standard Antibiotic Course Duration in Children <5 Years of Age Hospitalized With Community-acquired Pneumonia in High-risk Settings: Four-week Outcomes of a Multicenter, Double-blind, Parallel, Superiority Randomized Controlled Trial.
    McCallum GB; Fong SM; Grimwood K; Nathan AM; Byrnes CA; Ooi MH; Nachiappan N; Saari N; Morris PS; Yeo TW; Ware RS; Elogius BW; Oguoma VM; Yerkovich ST; de Bruyne J; Lawrence KA; Lee B; Upham JW; Torzillo PJ; Chang AB
    Pediatr Infect Dis J; 2022 Jul; 41(7):549-555. PubMed ID: 35476706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT.
    Barratt S; Bielicki JA; Dunn D; Faust SN; Finn A; Harper L; Jackson P; Lyttle MD; Powell CV; Rogers L; Roland D; Stöhr W; Sturgeon K; Vitale E; Wan M; Gibb DM; Sharland M
    Health Technol Assess; 2021 Nov; 25(60):1-72. PubMed ID: 34738518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-four Month Outcomes of Extended- Versus Standard-course Antibiotic Therapy in Children Hospitalized With Pneumonia in High-risk Settings: A Randomized Controlled Trial.
    Kok HC; McCallum GB; Yerkovich ST; Grimwood K; Fong SM; Nathan AM; Byrnes CA; Ware RS; Nachiappan N; Saari N; Morris PS; Yeo TW; Oguoma VM; Masters IB; de Bruyne JA; Eg KP; Lee B; Ooi MH; Upham JW; Torzillo PJ; Chang AB
    Pediatr Infect Dis J; 2024 Sep; 43(9):872-879. PubMed ID: 38830139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children (DACS): a multi-centre, double blind, randomised controlled trial.
    Ruffles TJC; Goyal V; Marchant JM; Masters IB; Yerkovich S; Buntain H; Cook A; Schultz A; Upham JW; Champion A; Versteegh L; Chang AB
    Lancet Respir Med; 2021 Oct; 9(10):1121-1129. PubMed ID: 34048716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HOspitalised Pneumonia Extended (HOPE) Study to reduce the long-term effects of childhood pneumonia: protocol for a multicentre, double-blind, parallel, superiority randomised controlled trial.
    Chang AB; Fong SM; Yeo TW; Ware RS; McCallum GB; Nathan AM; Ooi MH; de Bruyne J; Byrnes CA; Lee B; Nachiappan N; Saari N; Torzillo P; Smith-Vaughan H; Morris PS; Upham JW; Grimwood K
    BMJ Open; 2019 Apr; 9(4):e026411. PubMed ID: 31023759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shorter versus longer duration of Amoxicillin-based treatment for pediatric patients with community-acquired pneumonia: a systematic review and meta-analysis.
    R Marques I; P Calvi I; A Cruz S; M F Sanchez L; F Baroni I; Oommen C; H Padrao EM; C Mari P
    Eur J Pediatr; 2022 Nov; 181(11):3795-3804. PubMed ID: 36066660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
    Fogarty CM; Cyganowski M; Palo WA; Hom RC; Craig WA
    Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia.
    Benninger MS
    Expert Opin Pharmacother; 2003 Oct; 4(10):1839-46. PubMed ID: 14521493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
    Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT).
    Lyttle MD; Bielicki JA; Barratt S; Dunn D; Finn A; Harper L; Jackson P; Powell CVE; Roland D; Stohr W; Sturgeon K; Wan M; Little P; Faust SN; Robotham J; Hay AD; Gibb DM; Sharland M;
    BMJ Open; 2019 May; 9(5):e029875. PubMed ID: 31123008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.
    Bielicki JA; Stöhr W; Barratt S; Dunn D; Naufal N; Roland D; Sturgeon K; Finn A; Rodriguez-Ruiz JP; Malhotra-Kumar S; Powell C; Faust SN; Alcock AE; Hall D; Robinson G; Hawcutt DB; Lyttle MD; Gibb DM; Sharland M;
    JAMA; 2021 Nov; 326(17):1713-1724. PubMed ID: 34726708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
    Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
    Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial.
    Pernica JM; Harman S; Kam AJ; Carciumaru R; Vanniyasingam T; Crawford T; Dalgleish D; Khan S; Slinger RS; Fulford M; Main C; Smieja M; Thabane L; Loeb M
    JAMA Pediatr; 2021 May; 175(5):475-482. PubMed ID: 33683325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.
    Goyal V; Grimwood K; Ware RS; Byrnes CA; Morris PS; Masters IB; McCallum GB; Binks MJ; Smith-Vaughan H; O'Grady KF; Champion A; Buntain HM; Schultz A; Chatfield M; Torzillo PJ; Chang AB
    Lancet Respir Med; 2019 Sep; 7(9):791-801. PubMed ID: 31427252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial.
    Williams DJ; Creech CB; Walter EB; Martin JM; Gerber JS; Newland JG; Howard L; Hofto ME; Staat MA; Oler RE; Tuyishimire B; Conrad TM; Lee MS; Ghazaryan V; Pettigrew MM; Fowler VG; Chambers HF; Zaoutis TE; Evans S; Huskins WC;
    JAMA Pediatr; 2022 Mar; 176(3):253-261. PubMed ID: 35040920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-course antimicrobial therapy for paediatric respiratory infections (SAFER): study protocol for a randomized controlled trial.
    Pernica J; Harman S; Kam A; Bailey J; Carciumaru R; Khan S; Fulford M; Thabane L; Slinger R; Main C; Smieja M; Loeb M
    Trials; 2018 Feb; 19(1):83. PubMed ID: 29391051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic treatment of acute otorrhea through tympanostomy tube: randomized double-blind placebo-controlled study with daily follow-up.
    Ruohola A; Heikkinen T; Meurman O; Puhakka T; Lindblad N; Ruuskanen O
    Pediatrics; 2003 May; 111(5 Pt 1):1061-7. PubMed ID: 12728089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.